Melanocortin receptor agonist · Fact sheet

Melanotan II

Also known as Melanotan-2 · MT-II · MT2

Melanotan II is an unapproved peptide associated with skin pigmentation and sexual effects. Small trials reported erections and nausea; serious case reports raise additional concerns and do not establish a safe tanning use.

Not FDA approvedEarly human evidence

What is Melanotan II?

Melanotan II activates melanocortin pathways. It is different from the approved drugs afamelanotide and bremelanotide, and their approvals do not transfer to it.

Benefits & claims

Tanning, increased sexual desire, and erectile effects drive interest. A pigmentation change is not evidence of protection from ultraviolet damage.

What the evidence supports

  • Small studies found more erectile responses than placebo, with increased sexual desire in one study.
  • These experimental observations are not an FDA-approved indication.
Research areas
  • Erectile responses
  • Sexual desire
  • Melanocortin signaling

Dosage & frequency

No established human regimen

There is no FDA-approved melanotan II tanning or sexual-function regimen. Early human studies do not establish safe cosmetic use.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Melanotan II is distinct from approved bremelanotide and from afamelanotide.

Interactions & precautions

  • An established human interaction profile for cosmetic tanning use is lacking; early experiments do not establish combination safety.

What is still unresolved

  • A safe dose, frequency, product standard, and long-term skin or cardiovascular risk profile remain unestablished.

Side effects & risks

  • Nausea, yawning, stretching, and reduced appetite were reported in the small trials.
  • FDA cites serious case reports, including prolonged erections and melanoma; such reports do not establish incidence or causation.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Two small controlled crossover studies in men with erectile dysfunction found erectogenic effects. They do not establish everyday tanning safety, lasting sexual benefit, or applicability to other populations.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Greater libido with unwanted facial darkening

An author described better libido, mood and energy over two weeks, but unexpectedly dark facial pigmentation and much darker freckles, which prompted them to stop.

Reported use in this account

Product
Product described as melanotan II
Amount
0.25 mg
Frequency
Every day, as reported
Route
Not specified clearly
Duration
About two weeks

The product, UV exposure and skin changes were not clinically verified. This cannot identify or rule out a concerning mole change.

Read the original account

Approval status

Melanotan II is not FDA approved. It is not interchangeable with approved melanocortin medicines, and the cited small trials do not establish a current approval pathway.

No FDA-approved Melanotan II product

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term skin and cancer outcomes
  • The frequency of serious adverse events
  • Safety across populations and unverified products

Summary

Melanotan II has observable biological effects and substantial unresolved risks; a tan or sexual response is not proof of safety.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety concerns for selected bulk substances

    Ingredient-specific safety findings; compounding review is not drug approval.

  2. pubmedMelanotan II in men with organic erectile dysfunction

    Ten-person crossover study of erections, desire, and tolerability.

  3. pubmedMelanotan II in psychogenic erectile dysfunction

    Ten-person controlled crossover study; short follow-up and narrow population.

How we assess sources · Suggest a correction